A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
A phase 2 trial of Siltuximab and Melphalan in Multiple myeloma, run by Memorial Sloan Kettering Cancer Center, now recruiting.
Overview
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant is a phase 2 interventional study registered as NCT06679829 by Memorial Sloan Kettering Cancer Center, with 215 participants planned, started 2024-11-06 and due to reach its primary completion in 2027-11. Interventions recorded: Siltuximab, Melphalan. Conditions recorded: Multiple Myeloma.
Linked to the drug Siltuximab because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialSiltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Shares Siltuximab, Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialPercutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Shares Melphalan (including hepatic delivery system) and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialPanobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
Shares Melphalan (including hepatic delivery system) and the tag pipeline.
- TrialMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Shares Multiple myeloma and the tag pipeline.